Cell Discovery (May 2022)

Decoding the pathogenesis of Diamond–Blackfan anemia using single-cell RNA-seq

  • Bingrui Wang,
  • Chenchen Wang,
  • Yang Wan,
  • Jie Gao,
  • Yige Ma,
  • Yingnan Zhang,
  • Jingyuan Tong,
  • Yingchi Zhang,
  • Jinhua Liu,
  • Lixian Chang,
  • Changlu Xu,
  • Biao Shen,
  • Yumei Chen,
  • Erlie Jiang,
  • Ryo Kurita,
  • Yukio Nakamura,
  • Kim-Chew Lim,
  • James Douglas Engel,
  • Jiaxi Zhou,
  • Tao Cheng,
  • Xiaofan Zhu,
  • Ping Zhu,
  • Lihong Shi

DOI
https://doi.org/10.1038/s41421-022-00389-z
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 19

Abstract

Read online

Abstract Ribosomal protein dysfunction causes diverse human diseases, including Diamond–Blackfan anemia (DBA). Despite the universal need for ribosomes in all cell types, the mechanisms underlying ribosomopathies, which are characterized by tissue-specific defects, are still poorly understood. In the present study, we analyzed the transcriptomes of single purified erythroid progenitors isolated from the bone marrow of DBA patients. These patients were categorized into untreated, glucocorticoid (GC)-responsive and GC-non-responsive groups. We found that erythroid progenitors from untreated DBA patients entered S-phase of the cell cycle under considerable duress, resulting in replication stress and the activation of P53 signaling. In contrast, cell cycle progression was inhibited through induction of the type 1 interferon pathway in treated, GC-responsive patients, but not in GC-non-responsive patients. Notably, a low dose of interferon alpha treatment stimulated the production of erythrocytes derived from DBA patients. By linking the innately shorter cell cycle of erythroid progenitors to DBA pathogenesis, we demonstrated that interferon-mediated cell cycle control underlies the clinical efficacy of glucocorticoids. Our study suggests that interferon administration may constitute a new alternative therapeutic strategy for the treatment of DBA. The trial was registered at www.chictr.org.cn as ChiCTR2000038510.